Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.

The Netherlands journal of medicine

PubMedID: 24038559

Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. Neth J Med. 2013;71(7):342-7.
Background: Dysregulation of complement activation is the most common cause of the atypical haemolytic uraemic syndrome (aHUS). Many patients with aHUS develop end-stage renal disease and consider kidney transplantation. However, the recurrence rate after transplantation ranges from 45-90% in patients with known abnormalities in circulating complement proteins. It was recently proposed that patients with aHUS should be treated prophylactically with plasma exchange or eculizumab to prevent recurrence after transplantation. Methods: A case series describing the successful outcome of kidney transplantation without prophylactic therapy in four adult patients with aHUS and a high risk of disease recurrence. Patients received a living donor kidney and immunosuppression consisting of basiliximab induction, low-dose tacrolimus, prednisone and mycophenolate mofetil. Patients received a statin, and were targeted to a low blood pressure preferably using blockers of the renin-angiotensin system. Results: After a follow-up of 16-21 months, none of the patients developed recurrent aHUS. Also, no rejection was observed. Conclusions: Kidney transplantation in adult patients with aHUS can be successful without prophylactic eculizumab, using a protocol that minimises cold ischaemia time, reduces the risk of rejection and provides endothelial protection. Our data suggest that in patients with aHUS, controlled trials are needed to demonstrate the optimal strategy.